Non-Hodgkin's Lymphoma Articles | Page 2

Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy
Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.
Expert Emphasizes Importance of Acalabrutinib Approval in MCL
Michael Wang, MD, discusses the impact of acalabrutinib on patients with mantle cell lymphoma, ongoing progress in the field, and The University of Texas MD Anderson Cancer Center
Goy Reflects on MCL Data Presented at ASH 2017
Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).
Combinations Have Potential to Shift CLL Treatment Paradigm
Richard Furman, MD, discusses the current management of chronic lymphocytic leukemia and the future of combinations, including venetoclax and ibrutinib, for this patient population.
CLL in the Era of Targeted Therapies
Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.
The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. 
Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL
Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.
Atezolizumab Triplet Achieves 75% CR Rate in Frontline Follicular Lymphoma
The frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma, according to findings from a phase Ib/II trial.
FDA Grants Priority Review to Pembrolizumab for Relapsed/Refractory PMBCL
The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Rituximab Leads to Faster Response in CLL, But PFS Not Improved
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL. 
Publication Bottom Border
Border Publication